First Indian vaccine manufacturer to successfully produce a thimerosal-free Hepatitis B Vaccine

PRLog (Press Release) – Oct 30, 2007 – Bharat Biotech once again becomes the first Indian vaccine manufacturer to successfully produce Revac-Bmcf, a thimerosal -free Hepatitis B Vaccine and usher in an era of preferred vaccines. A thimerosal -free hepatitis vaccine is preferred choice of pediatricians for birth dose vaccination of new born babies within 12 hours of birth. The launch of Revac-Bmcf (thimerosal-free) at an affordable price by Bharat Biotech will also address the needs of parents and members of the medical fraternity who prefer the use of thimerosal -free vaccines.

Globally, Seven multinational companies (MNC’s) manufacture thimerosal -free vaccines such as Hepatitis B, Flu, Hepatitis A, DTaP, DTap+HepB+IPV, Hib, Hib+Hep B, HPV, IPV, MMR, MMR+Varicella, Pneumococcal, Rabies, Typhoid and Yellow Fever vaccines for use in markets worldwide. Bharat Biotech joins this elite club of vaccine manufacturers in developing, manufacturing and commercializing thimerosal -free vaccines. Several other vaccines in the current product line and future pipeline of Bharat Biotech will also be developed and commercialized in thimerosal -free presentations.

Bharat Biotech has a successful track record of manufacturing a Thimerosal -free pediatric vaccine for a highly reputed MNC on a contract basis for overseas regulated markets. Having succeeded as the first Indian vaccine manufacturer to eliminate the use of Cesium chloride in Hepatitis B Vaccines, Bharat Biotech is forging ahead with a current portfolio of 10 injectable sterile preparations including 7 vaccines.

Bharat Biotech has effectively optimized its production technologies to ensure the phasing out of thimerosal as a preservative wherever possible.